Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-11

  Draghiciu, Oana ^a   Nijman, Hans W ^a   Hoogeboom, Baukje Nynke ^a   Meijerhof, Tjarko ^a   Daemen, Toos ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cancer vaccine; Myeloid derived suppressor cells; Semliki Forest virus; Sunitinib; Suppressive factors

Indexed keywords

CANCER VACCINE; CD69 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SUNITINIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR IMMUNITY; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84946950382     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.989764     Document Type: Article

References (63)

1. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174:7516-23; PMID:15944250; http://dx.doi.org/10.4049/jimmunol.174.12.7516
2. Draghiciu O, Walczak M, Hoogeboom BN, Franken KL, Melief KJ, Nijman HW, Daemen T. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int J Cancer 2014; 134 (4):859-72; PMID:23922012; http://dx.doi.org/10.1002/ijc.28418
3. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200:771-82; PMID:15381730; http://dx.doi.org/10.1084/jem.20041130
4. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
5. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn- Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, et al. Monocytic CCR2 (C) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72:876-86; PMID:22174368; http://dx.doi.org/10.1158/0008-5472.CAN-11-1792
6. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013; 190:3783-97; PMID:23440412; http://dx.doi.org/10.4049/jimmunol.1201449
7. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117:1155-66; PMID:17476345; http://dx.doi.org/10.1172/JCI31422
8. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
9. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013; 62:909-18; PMID:23589106; http://dx.doi.org/10.1007/s00262-013-1396-8
10. Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLOS ONE 2012; 7:e40677; PMID:22815789; http://dx.doi.org/10.1371/journal.pone.0040677
11. Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ. Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer 2013; 11:297-302; PMID:23707221; http://dx.doi.org/10.1016/j.clgc.2013.04.001
12. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-24; PMID:17215529; http://dx.doi.org/10.1056/NEJMoa065044
13. Bayraktar UD, Bayraktar S, Rocha-Lima CM. Molecular basis and management of gastrointestinal stromal tumors. World J Gastroenterol 2010; 16:2726-34; PMID:20533592; http://dx.doi.org/10.3748/wjg.v16.i22.2726
14. Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006; 5:1280-9; PMID:16731761; http://dx.doi.org/10.1158/1535-7163.MCT-03-0156
15. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185:2273-84; PMID:20644162; http://dx.doi.org/10.4049/jimmunol.1000901 [doi]
16. Pan PY, Wang GX, Yin B, Ozao J, Ku T, Divino CM, Chen SH. Reversion of immune tolerance in advanced malignancy: Modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111:219-28; PMID:17885078; http://dx.doi.org/10.1182/blood-2007-04-086835 [pii].
17. Kato M, Takeda K, Kawamoto Y, Tsuzuki T, Hossain K, Tamakoshi A, Kunisada T, Kambayashi Y, Ogino K, Suzuki H, et al. C-kit-targeting immunotherapy for hereditary melanoma in a mouse model. Cancer Res 2004; 64:801-6; PMID:14871802; http://dx.doi.org/10.1158/0008-5472.CAN-03-2532
18. Voron T, Marcheteau E, Pernot S, Colussi O, Tartour E, Taieb J, Terme M. Control of the immune response by pro-angiogenic factors. Front Oncol 2014; 4:70; PMID:24765614; http://dx.doi.org/10.3389/fonc.2014.00070
19. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloidderived suppressor cells promote cross-tolerance in Bcell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68:5439-49; PMID:18593947; http://dx.doi.org/10.1158/0008-5472.CAN-07-6621
20. Lindsey WB, Lowdell MW, Marti GE, Abbasi F, Zenger V, King KM, Lamb LS, Jr. CD69 expression as an index of T-cell function: Assay standardization, validation and use in monitoring immune recovery. Cytotherapy 2007; 9:123-32; PMID:17453964; http://dx.doi.org/10.1080/14653240601182838
21. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
22. Daemen T, Riezebos-Brilman A, Regts J, Dontje B, van der Zee A, Wilschut J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: Effects of the route of immunization. Antivir Ther 2004; 9:733-42; PMID:15535411
23. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69:2506-13; PMID:19244102; http://dx.doi.org/10.1158/0008-5472.CAN-08-4323
24. Sorolla A, Yeramian A, Valls J, Dolcet X, Bergada L, Llombart-Cussac A, Marti RM, Matias-Guiu X. Blockade of NFkappaB activity by sunitinib increases cell death in bortezomib-treated endometrial carcinoma cells. Mol Oncol 2012; 6:530-41; PMID:22819259; http://dx.doi.org/10.1016/j.molonc.2012.06.006 [doi].
25. Martinho O, Silva-Oliveira R, Miranda-Goncalves V, Clara C, Almeida JR, Carvalho AL, Barata JT, Reis RM. In vitro and in vivo analysis of RTK inhibitor efficacy and identification of its novel targets in glioblastomas. Transl Oncol 2013; 6:187-96; PMID:23544171; http://dx.doi.org/10.1593/tlo.12400
26. Bronte V, Serafini P, Apolloni E, Zanovello P. Tumorinduced immune dysfunctions caused by myeloid suppressor cells. J Immunother 2001; 24:431-46; PMID:11759067; http://dx.doi.org/10.11207/jimmunother.1524-9557
27. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 2001; 166:678-89; PMID:11123353; http://dx.doi.org/10.4049/jimmunol.166.1.678
28. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: Immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
29. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69:2514-22; PMID:19276342; http://dx.doi.org/10.1158/0008-5472.CAN-08-4709
30. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic gr-1C/CD11bC myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-21; PMID:16166452; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883
31. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-24; PMID:16757724; http://dx.doi.org/10.1001/jama.295.21.2516
32. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25-35; PMID:16314617; http://dx.doi.org/10.1200/JCO.2005.02.2194
33. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-37; PMID:12538485; http://dx.doi.org/10.1158/1078-0432.CCR-02-2832
34. Molina AM, Motzer RJ, Heng DY. Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Semin Oncol 2013; 40:436-43; PMID:23972707; http://dx.doi.org/10.1053/j.seminoncol.2013.05.013
35. Cao M, Xu Y, Youn JI, Cabrera R, Zhang X, Gabrilovich D, Nelson DR, Liu C. Kinase inhibitor sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest 2011; 91:598-608; PMID:21321535; http://dx.doi.org/10.1038/labinvest.2010.205
36. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332
37. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70:3526-36; PMID:20406969; http://dx.doi.org/10.1158/0008-5472.CAN-09-3278
38. Porta C, Paglino C, Imarisio I, Ganini C, Pedrazzoli P. Immunological effects of multikinase inhibitors for kidney cancer: A clue for integration with cellular therapies? J Cancer 2011; 2:333-8; PMID:21716852; http://dx.doi.org/10.1074/jc.v2.3119398
39. de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007; 9:412-23; PMID:17622648; http://dx.doi.org/10.1215/15228517-2007-024
40. Bampi VF, Gomes CF, De Oliveira LB, Da Silva JL. The effect of the anti-angiogenic drug sunitinib malate on the vascular architecture of oral squamous cell carcinoma. Microsc Res Tech 2014; 77(4):250-6; PMID:24458724; http://dx.doi.org/10.1002/jemt.22336
41. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10:130-7; PMID:20094047; http://dx.doi.org/10.1038/nrc2787
42. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res 2014; 74:104-18; PMID:24197130; http://dx.doi.org/10.1158/0008-5472.CAN-13-1545
43. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111:5610-20; PMID:18310500; http://dx.doi.org/10.1182/blood-2007-02-075945
44. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011; 11:856-61; PMID:21315783; http://dx.doi.org/10.1016/j.intimp.2011.01.030
45. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008; 118:3367-77; PMID:18776941; http://dx.doi.org/10.1172/JCI35213
46. Walczak M, Regts J, van Oosterhout AJ, Boon L, Wilschut J, Nijman HW, Daemen T. Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. Antivir Ther 2011; 16:207-18; PMID:21447870; http://dx.doi.org/10.3851/IMP1751
47. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, et al. Transforming growth factorbeta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence. J Exp Med 2003; 198:1741-52; PMID:14657224; http://dx.doi.org/10.1084/jem.20022227
48. Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2012; 130:1948-59; PMID:21633954; http://dx.doi.org/10.1002/ijc.26219
49. Riezebos-Brilman A, Walczak M, Regts J, Rots MG, Kamps G, Dontje B, Haisma HY, Wilschut J, Daemen T. A comparative study on the immunotherapeutic efficacy of recombinant semliki forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther 2007; 14:1695-704; PMID:17928874; http://dx.doi.org/10.1038/sj.gt.3303036
50. Jaini R, Rayman P, Cohen PA, Finke JH, Tuohy VK. Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer 2014; 134:1695-705; PMID:24105638; http://dx.doi.org/10.1002/ijc.28488
51. Lambeck AJ, Nijman HW, Hoogeboom BN, Regts J, de Mare A, Wilschut J, Daemen T. Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. Vaccine 2010; 28:4275-82; PMID:20434555; http://dx.doi.org/10.1016/j.vaccine.2010.04.033
52. Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21-6; PMID:8548765
53. Ribechini E, Leenen PJ, Lutz MB. Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. Eur J Immunol 2009; 39:3538-51; PMID:19830733; http://dx.doi.org/10.1002/eji.200939530
54. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262
55. Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P, Schwendener RA, Bai XF, Shilo K, Zou X, et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 2012; 72:604-15; PMID:22158945; http://dx.doi.org/10.1158/0008-5472.CAN-11-0669
56. Ruiz PA, Shkoda A, Kim SC, Sartor RB, Haller D. IL-10 gene-deficient mice lack TGF-beta/smad signaling and fail to inhibit proinflammatory gene expression in intestinal epithelial cells after the colonization with colitogenic enterococcus faecalis. J Immunol 2005; 174:2990-9; PMID:15728512; http://dx.doi.org/10.4049/jimmunol.174.5.2990
57. He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D, Feng ZH. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol 2004; 173:4919-28; PMID:15470033; http://dx.doi.org/10.4049/jimmunol.173.8.4919
58. Meng Q, Yang P, Li B, Zhou H, Huang X, Zhu L, Ren Y, Kijlstra A. CD4CPD-1C T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci 2006; 47:4444-52; PMID:17003438; http://dx.doi.org/10.1167/iovs.06-0201
59. Janakiram NB, Rao CV. iNOS-selective inhibitors for cancer prevention: Promise and progress. Future Med Chem 2012; 4:2193-204; PMID:23190107; http://dx.doi.org/10.4155/fmc.12.168
60. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. Arginases I and II: Do their functions overlap? Mol Genet Metab 2004; 81 Suppl 1:S38-44; PMID:15050972; http://dx.doi.org/10.1016/j.ymgme.2003.10.012
61. Sousa MS, Latini FR, Monteiro HP, Cerutti JM. Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors. Free Radic Biol Med 2010; 49:997-1007; PMID:20542107; http://dx.doi.org/10.1016/j.freeradbiomed.2010.06.006
62. Sevko A, Umansky V. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: Thick as thieves. J Cancer 2013; 4:3-11; PMID:23386900; http://dx.doi.org/10.7150/jca.5047
63. Juhasz A, Ge Y, Markel S, Chiu A, Matsumoto L, van Balgooy J, Roy K, Doroshow JH. Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free Radic Res 2009; 43:523-32; PMID:19431059; http://dx.doi.org/10.1080/10715760902918683